Ultan McDermott

Chief Scientist

AstraZeneca UK Limited

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Ultan McDermott is the Chief Scientist at AstraZeneca UK Ltd. His research focuses on the intersection of machine learning and oncology, particularly in colorectal cancer, rectal cancer, and melanoma. Recent publications include studies on tumour purity assessment, cetuximab sensitivity, and predictive models for response to radiation. His work contributes to understanding drug resistance and improving therapeutic strategies in cancer treatment.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (16)

Nicholas West

University of Leeds School of Medicine

UNITED KINGDOM

Ultan McDermott

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Tumour purity assessment with deep learning in colorectal cancer and impact on molecular analysis

Integrative ensemble modelling of cetuximab sensitivity in colorectal cancer patient-derived xenografts.

Identification and validation of a machine learning model of complete response to radiation in rectal cancer reveals immune infiltrate and TGFβ as key predictors.

Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations.

Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer.

The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.

Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

Mutually exclusive genetic interactions and gene essentiality shape the genomic landscape of primary melanoma.

Pharmaceutical Reactivation of Attenuated Apoptotic Pathways Leads to Elimination of Osimertinib Drug-Tolerant Cells.

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists.

Collaborators (16)

Nicholas West

Scott Tagawa

Orsetta Quaini

Charlotte Tolley

Philip Dunne

Andy Lynch

Daniel Brewer

Rosalind Eeles

Jingjing Zhang

Leslie Samuel

Timothy Stanley Maughan

Larissa Matsuyama

Marieke Lydia Kuijjer

Alessandro Romanel

David Sebag-Montefiore

Marco Viviani

Make your next move.